Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
*Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets*YUPELRI expected to contribute immediately accretive revenue and cash flow to
